Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharm (NQ: SUPN )

36.88 +0.66 (+1.84%)
Streaming Delayed Price Updated: 10:30 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,036
Open 36.55
Bid (Size) 36.81 (8)
Ask (Size) 36.96 (8)
Prev. Close 36.22
Today's Range 36.31 - 37.21
52wk Range 25.53 - 39.37
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Third Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+33.01%
+33.01%
1 Month
+8.71%
+8.71%
3 Month
+5.78%
+5.78%
6 Month
+36.26%
+36.26%
1 Year
+36.16%
+36.16%

More News

Read More
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Second Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals.
Via Chartmill
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents.
Via Chartmill
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.